BAYN - IPO Update: Phathom Pharmaceuticals Proposes IPO Terms
Quick Take
Phathom Pharmaceuticals (PHAT) intends to raise $150 million from an IPO, per an S-1/A registration statement.
The company is advancing a drug treatment for GERD, a common gastrointestinal condition.
For life science investors with at least a 24-month hold timeframe, the IPO may be worth considering.
Company & Technology
Buffalo Grove, Illinois-based Phathom was founded in 2018 to develop and commercialize new treatments for GI diseases.
Management is headed by President, CEO, and Treasurer David Socks, who has been with the firm since 2018 and has previously co-founded Incline